Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Barbara S. Craft"'
Autor:
Mary R. Nittala, Eswar K. Mundra, S. Packianathan, Divyang Mehta, Maria L. Smith, William C. Woods, Shawn McKinney, Barbara S. Craft, Srinivasan Vijayakumar
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background The Will Rogers phenomenon [WRP] describes an apparent improvement in outcome for patients’ group due to tumor grade reclassification. Staging of cancers is important to select appropriate treatment and to estimate prognosis. Th
Externí odkaz:
https://doaj.org/article/dd41572ad9e54a8abb3743cc71c08483
Autor:
Srinivasan Vijayakumar, Mary R Nittala, Vedanth Buddala, Paul Mobit, William N Duggar, Claus Chunli Yang, Seth T Lirette, Eswar Mundra, Hiba Z Ahmed, Scott M Berry, Barbara S Craft, William C Woods, Jeremy Otts, Asal Rahimi, Thomas Dobbs
Publikováno v:
Cureus.
Autor:
Carter Louis Capra, Shou-Ching Tang, Simon Mairs, Barbara S. Craft, William B. Hillegass, Xiaofu Zhu, Judith Meza-Junco, Germame Ajebo
Publikováno v:
Cancer Research. 80:P3-08
Introduction: The plant alkaloid Maytansine and its derivatives with anti-microtubule activity failed in early trials due to significant toxicity.When linked to trastuzumab as an antibody-drug conjugate (ADC), emtansine can be delivered directly into
Autor:
Eswar K. Mundra, Satyaseelan Packianathan, Shawn McKinney, Barbara S. Craft, Grace G. Shumaker, William C. Woods, Lacey Weatherall, Maria L. Smith, Gary L. Shultz, Mary R Nittala, Scott M. Berry, Paul Russell Roberts, Divyang Mehta, Srinivasan Vijayakumar, Dennis P. Morgan
Background Triple negative breast cancer (TNBC) (estrogen receptor (ER) – negative, progesterone receptor (PR) - negative, and human epidermal growth factor receptor 2 (HER2) -negative) is an aggressive subtype of breast cancer that is more common
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89528842524a6fc1e5b969d9f4a197da
https://doi.org/10.21203/rs.3.rs-638570/v1
https://doi.org/10.21203/rs.3.rs-638570/v1
Autor:
Simon Mairs, Nita J. Maihle, Shou-Ching Tang, Barbara S. Craft, William B. Hillegass, Xiaofu Zhu, Judith Meza-Junco, Germame Ajebo, Carter Louis Capra
Publikováno v:
International Journal of Cancer
The mechanism by which trastuzumab‐emtansine (T‐DM1) causes systemic toxicities apart from trastuzumab alone is currently unknown. We hypothesized that the systemic toxicities from T‐DM1 may have been caused by the free and active maytansine re
Autor:
Eswar K. Mundra, Mary R Nittala, Shawn McKinney, Divyang Mehta, Srinivasan Vijayakumar, William C. Woods, Maria L. Smith, Barbara S. Craft, Satyaseelan Packianathan
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Background The Will Rogers phenomenon [WRP] describes an apparent improvement in outcome for patients’ group due to tumor grade reclassification. Staging of cancers is important to select appropriate treatment and to estimate prognosis. The WRP has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74db9096da60f0195afa046b75b13faf
https://doi.org/10.21203/rs.3.rs-48135/v1
https://doi.org/10.21203/rs.3.rs-48135/v1
Autor:
S. Packianathan, Shawn McKinney, Divyang Mehta, William C. Woods, Maria L. Smith, Mary R Nittala, Srinivasan Vijayakumar, Eswar K. Mundra, Barbara S. Craft
Publikováno v:
Cancer Research. 80:6177-6177
Purpose: The objective of this study is to evaluate local control and survival rates of node negative triple negative breast cancer patients (TNBCs) treated with radiotherapy (RT) in our institution. Methods: This is a retrospective analysis of 67 TN
Autor:
Shawn McKinney, Eswar K. Mundra, Mary R Nittala, Srinivasan Vijayakumar, William C. Woods, Divyang Mehta, Barbara S. Craft, Satyaseelan Packianathan
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 29:B126-B126
Purpose: To assess whether the Will Roger’s phenomenon [WRP] exists with the move from the AJCC 7th to AJCC 8th edition in Breast Cancer staging and if racial differences are manifested in the expression of the WRP. Methods: A retrospective analysi
Autor:
Yu-Wen Chiu, Karen Meneses, Laura Ricks, Timiya S. Nolan, Barbara S. Craft, Silvia Gisiger Camata, Donna L. Williams
Publikováno v:
Health promotion practice. 21(2)
In the United States, about 11% (26,393) of those diagnosed with breast cancer in 2016 will be young or less than 45 years old. Young breast cancer survivors, compared to older cancer survivors, are a disparate group that experience higher incidence
Publikováno v:
Experimental and Molecular Pathology. 95:174-179
We aimed to examine the use of circulating tumor cells (CTCs) as an effective measure of treatment efficacy and immune system function in metastatic breast cancer patients. CTCs are believed to be indicators of residual disease and thus pose an incre